SALT LAKE CITY, Nov. 12, 2025 /PRNewswire/ -- Governor Spencer Cox joins Kelvyn Cullimore of BioUtah in recognizing Co-Diagnostics, Inc. (Nasdaq: CODX), a Utah diagnostics company with a patented platform for developing advanced molecular diagnostic tests, following its recent announcement of the formation of CoMira Diagnostics, a joint venture (JV) in the Kingdom of Saudi Arabia.
"Co-Diagnostics is a Utah-born company competing on the world stage," said Governor Spencer Cox. "Their expansion across the Middle East and North Africa reflects the strength of Utah's life sciences and the grit of our entrepreneurs. We're proud to see a Utah company building tools that help more patients around the world."
Kelvyn Cullimore, President and CEO of BioUtah, added "BioUtah is proud to count Co-Diagnostics among its Elite members. Their recent signing of a definitive JV agreement with a company in the Kingdom of Saudi Arabia (KSA) further confirms Co-Diagnostics' expanding leadership and presence on the worldwide stage. We couldn't be more pleased with the way they represent the Utah life sciences community, one of the fastest growing in the United States."
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

| Last Trade: | US$0.24 |
| Daily Volume: | 0 |
| Market Cap: | US$14.310M |
December 29, 2025 December 17, 2025 December 09, 2025 November 20, 2025 November 18, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load